Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

Ali Taher*, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler-Krahn, Ali El-Ali, Bernard Roubert, Amal El-Beshlawy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry